The top five episodes of our podcast in the year 2024, highlighted.
Related Posts
RSV Vaccine Arexvy Shows Potential for Expanded Use in At-Risk Adults Aged 18-49, Including Immunocompromised
Credit: Julia | stock.adobe.com A pair of clinical trials demonstrated that GSK’s respiratory syncytial virus (RSV) vaccine Arexvy produced a…
FDA Fast Tracks Ovarian Cancer Drug Currently in Phase II Trial
Image credit: blueringmedia | stock.adobe.com The FDA has granted Fast Track Designation (FTD) to RemeGen Co. Ltd’s mesothelin-targeting antibody-drug conjugate…
Rethinking Feasibility in the Attention Economy
Hugo Stephenson, MD, Co-Founder and Executive Chair, TrialScreen Key Takeaways Eligibility ≠ participation. While many users meet trial eligibility criteria,…